The regulatory landscape for cell and gene therapies (CGTs) is shifting faster than ever. With new FDA leadership at CBER, draft guidance on post-approval CMC requirements, and potency assays under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback